Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCT-810 in Ornithine Transcarbamylase Deficiency
NCT05526066Phase 2Terminated
- Sponsor
- Arcturus Therapeutics
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in ornithine transcarbamylase deficiency comparing ARCT-810 with Placebo (2 arms). Primary endpoint: Adverse Events at 23 weeks. Started Oct 2022; status: terminated.
02
Drugs
ARCT-810
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT05526066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526066.